Despite reporting improved financial results for FY25, Sonic Healthcare Limited (ASX:SHL) saw its share price drop sharply today, closing down 12.84% at $25.05, with markets looking for stronger growth from the healthcare provider in the guide.
Today’s pullback came despite Sonic Healthcare posting an 8% increase in revenue to $9,645 million and a 7% lift in net profit to $514 million. EBITDA also rose by 8% to $1,725 million, while cash generated from operations surged 21% to $1,297 million. Organic revenue growth reached 5%. The company declared a final dividend of 63 cents per share, 35% franked, bringing the full-year increase to 1 cent.
Operationally, Sonic Healthcare completed the acquisition of LADR Laboratory Group in Germany on July 1, 2025. LADR generated €370 million in revenue for 2024 and is expected to contribute immediate earnings. The company also secured a significant contract with Hertfordshire and West Essex NHS in the UK, which transferred 600 staff and delivered 14% organic growth for its UK operations. In Australia, Sonic renewed the National Bowel Screening contract and secured new private hospital laboratory service wins. The Radiology division demonstrated strong performance with 10% organic revenue and 12% EBITDA growth. The US business, after facing challenges, returned to positive organic growth in July 2025.
Looking ahead to FY2026, Sonic Healthcare anticipates strong earnings growth, projecting EPS growth of up to 19%. This outlook is based on continued organic growth, synergy realization from recent acquisitions in Switzerland, Germany, and the USA, and the integration of LADR and Cairo Diagnostics.
The decline in SHL brought the share price into negative territory on a YTD and 12 months basis, down 8.41% and 9.63% respectively. Erasing recent gains in one swoop tells it’s own story, future sessions could well be even more illuminating as we see if bulls find a level to step back in as support.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Bull Case:
- Strong FY25 results show solid revenue and profit growth.
- Acquisition of LADR strengthens position in Germany.
- Positive EPS growth of up to 19% projected for FY26.
Bear Case:
- Market expected even stronger growth, leading to share price drop.
- US business faced headwinds, indicating potential regional vulnerabilities.
- High expectations may create pressure for future performance.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2025.
We’re giving away this valuable research for FREE.
Click below to secure your copy
